Genomma Lab Internacional SAB de CV Class B ( (GNMLF) ) has released its Q4 earnings. Here is a breakdown of the information Genomma Lab Internacional SAB de CV Class B presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Genomma Lab Internacional, S.A.B. de C.V. is a leading pharmaceutical and personal care products company in Mexico, known for its broad range of premium branded products and a growing international presence.
In its latest earnings report, Genomma Lab announced a strong financial performance for the fourth quarter and full year 2024, highlighted by significant increases in net sales and profitability. The company reported a 32.4% increase in net sales for Q4 and a 13.0% increase for the full year, alongside a record free cash flow of Ps. 2.8 billion.
Key financial metrics showed robust growth, with EBITDA margins expanding to 24.0% in Q4 and 23.3% for the year, driven by manufacturing efficiencies and cost containment initiatives. Net income surged to Ps. 473.5 million in Q4, a notable recovery from the previous year’s losses, and full-year EPS doubled to Ps. 2.14. The company also achieved market share gains across several core categories, with beverages and analgesics showing particularly strong growth.
Looking ahead, Genomma Lab’s management remains optimistic, focusing on reinvesting savings from productivity gains to strengthen core brands and pursuing a cost savings target of Ps. 1.8 billion by 2027. The company aims to continue its growth trajectory by leveraging its strong cash position and expanding its market presence.